Objective. Interstitial lung diseases (ILDs) complicated with PM or DM are frequently aggressive and refractory to treatment. Recently some reports have suggested the potential benefit of tacrolimus for severe ILD complicated with PM/DM. However, little evidence has yet shown the efficacy of tacrolimus in these settings. The aim of this study was to evaluate the efficacy of tacrolimus as a treatment for PM-/DM-related ILD.
Introduction
PM and DM are systemic autoimmune diseases that affect skeletal muscle as well as organs such as the lung, heart and joints [1] . Among such organ involvement, pulmonary complications represented by interstitial lung disease (ILD) are found in 50% of PM/DM patients [2] and are recognized as common causes of mortality and morbidity in this disease [2, 3] . ILD in patients with clinically amyopathic DM (CADM) includes acute, progressive and severe forms that are pathologically referred to as diffuse alveolar damage [4, 5] , being resistant and refractory to treatment.
Although high-dose corticosteroid treatment is the first choice for PM-/DM-related ILD, the choice of a secondary immunosuppressive agent is a matter of controversy. CYC is one of the most commonly selected treatments for ILD in systemic autoimmune diseases, including PM/DM [6] . However, neither randomized, multicentre nor placebo-controlled trials have been conducted so far.
Recently the effectiveness of tacrolimus in PM-/DMrelated ILD, especially refractory or severe forms of this disease, has been shown in several case reports and retrospective studies [7, 8] . Tacrolimus has an immunosuppressive mode of action similar to ciclosporin, but binds to different intracellular receptors [9] . However, in vitro, tacrolimus has up to 100-fold stronger inhibitory effect on T cell proliferation and cytokine production than ciclosporin [10] . In the area of transplantation, several randomized controlled trials have confirmed the superior clinical efficacy and safety of tacrolimus compared with ciclosporin. Tacrolimus has been shown to improve the graft survival of kidney [11] and liver [12] and to decrease the severity of acute graft-vs-host disease in bone marrow transplantation [13] compared with ciclosporin. Therefore we hypothesized that tacrolimus is more effective than ciclosporin for the treatment of severe autoimmune conditions, including PM-/DM-related ILD.
In the analysis of observational studies, the propensity score is used as an analytical method that estimates the efficacy of intervention by considering the covariates predicting the selection of a certain therapy [14] . In the present study we aimed to evaluate the efficacy of tacrolimus treatment for PM-/DM-related ILD using adjustment by inverse probability of treatment weighting (IPTW) methods in order to minimize bias in the assessment of retrospectively collected data.
Patients and methods

Study design
The present retrospective, observational clinical study was conducted in a single centre to see if PM-/DM-related ILD patients treated with tacrolimus have a better prognosis compared with those treated with a conventional regimen. The study was approved by the ethics committee of Hokkaido University Hospital (permission number 012-0048).
The medical records of consecutive untreated PM-/DMrelated ILD patients admitted to Hokkaido University Hospital from January 2000 to July 2013 were reviewed retrospectively. The diagnosis was based on Bohan and Peter's criteria [1] in PM/DM and Sontheimer's criteria [15] in CADM. Inclusion body myositis, malignancy-associated or overlapping cases were excluded.
All patients were treated with high doses of prednisolone (0.81.0 mg/kg/day). In severe cases, i.v. methylprednisolone pulse therapy (1000 mg/day for 3 days) and/or another immunosuppressive agent such as ciclosporin (23 mg/kg/day), i.v. CYC (500 mg/m 2 /month) or tacrolimus were combined according to the decision of the treating physicians. In all cases treated with i.v. CYC, this agent was administered within 1 month from the initiation of immunosuppressive treatment. Tacrolimus was started orally at a dose of 13 mg/day, followed by adjustment to trough levels of 520 ng/ml.
We divided the patients into two groups based on the treatment protocol including or excluding tacrolimus. The conventional therapy group was defined as the patients treated with corticosteroids alone or in combination with other immunosuppressive agents except tacrolimus. The tacrolimus group was defined as the patients treated with tacrolimus as induction therapy within 28 days from the start of treatment.
Laboratory and physical findings
Serum lactate dehydrogenase (LDH), creatine kinase (CK) and Krebs von den Lungen-6 (KL-6), one of the markers of lung fibrosis, were determined. Manual muscle testing (MMT) was assessed for the following 18 muscles: the flexor and extensor muscles of the neck, the bilateral side of the deltoid, biceps brachii, brachioradialis, triceps brachii, iliopsoas, gluteus maximus, quadriceps femoris and hamstring. Each muscle was scored on a scale of 05 and the total score was evaluated as previously reported [16] .
Evaluation of ILD
All patients underwent high-resolution CT (HRCT) for diagnosis of ILD. Radiographic abnormalities consistent with ILD were determined by radiologists as follows: nodules, irregular linear opacities, ground glass opacities (GGOs), honeycombing and traction bronchiectases.
The following parameters concerning pulmonary function were evaluated by spirometry: forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), the FEV 1/ FVC ratio and the diffusing capacity for carbon monoxide (DL CO ).
Endpoints
The primary endpoint was defined as the time from the initiation of immunosuppressive treatment to relapse or death of respiratory cause or serious adverse event (SAE). Secondary endpoint was defined as time from the initiation of immunosuppressive treatment to relapse or death of respiratory cause. Relapse was defined as fulfilling all attributes as follows: (i) worsening of symptoms or hypoxia, (ii) radiological progression of ILD assessed by both radiologists and rheumatologists and (iii) the need for treatment with an increased dose of steroids (>0.5 mg/kg/ day) or with other immunosuppressive agents. SAEs were defined as death or hospitalization for any cause.
In the tacrolimus group, patients were censored at the time tacrolimus was discontinued. In the conventional group, patients were censored at the time tacrolimus administration was started. Patients without events were censored in August 2013.
Statistical analysis
All clinical data were compared between the tacrolimus group and the conventional therapy group. In independent samples, either a chi-squared test or Fisher's exact test was used for binary data and either a t-test or the MannWhitney U-test was used for continuous data. Survival curves were constructed by KaplanMeier methods and hazard ratios (HRs) and 95% CIs were estimated by Cox proportional hazard regression analysis. Primary and secondary endpoints were compared between the both groups by the adjusted Cox regression model using IPTW [17] .
The propensity score is the probability of treatment assignment (tacrolimus use) conditional on measured baseline variables. We selected predictive variables for tacrolimus use from several possible confounders (age, sex, disease duration, DM, amyopathic manifestation, anti-Jo-1 antibody, oxygen administration, acute progression within 60 days, serum KL-6 levels, FVC, CYC use, GGO and extensive ILD), which shows the highest likelihood score statistic in all possible logistic regression models. After variable selection, the propensity score was calculated for each patient using a logistic regression model including age, sex, disease duration, DM, anti-Jo-1 antibody, serum KL-6 levels, FVC, CYC use and GGO.
The probability that a patient had his or her own observed treatment was calculated using the propensity score. We used the inverse of the probability as a weight in the IPTW analysis [14] . The weight for a patient receiving tacrolimus was the inverse of the propensity score value, and the weight for each patient not receiving tacrolimus was the inverse of 1 minus the propensity score. In the weighted sample, the KaplanMeier curve was depicted and the adjusted HR and a robust 95% CI were estimated in a Cox regression model.
All P-values are two-tailed and those <0.05 were considered statistically significant. Data were analysed with SAS version 9.2 (SAS Institute, Cary, NC, USA) and SPSS version 19.0.0 software (SPSS Japan, Tokyo, Japan).
Results
Baseline characteristics
A total of 49 patients (17 PM and 32 DM) were enrolled in this study. The median observation period was 25.7 months [interquartile range (IQR) 12.046.5]. Steroid pulse therapy, ciclosporin and i.v. CYC were given to 28, 7 and 11 patients, respectively. Table 1 shows the demographic and baseline clinical features of the tacrolimus group and the conventional therapy group. Ciclosporin was given more in the conventional group and CYC was given more in the tacrolimus group.
Outcomes
In the tacrolimus group and the conventional therapy group, 5 (20.8%) and 5 (20.0%) patients relapsed, 1 (4.2%) and 5 (20.0%) died of a respiratory cause and 1 (4.2%) and 2 (8.0%) developed other SAEs, respectively. All relapses were from a respiratory cause. Distributions of SAEs were one patient with hepatic cirrhosis in the tacrolimus group and two with malignancy in the conventional therapy group. Muscular lesions evaluated by MMT and serum CK levels and respiratory lesions evaluated by FVC and DL CO were improved after 1 year of treatment, but no significant difference was found between the two groups (see supplementary Table S1 , available at Rheumatology Online).
Safety
Non-SAEs were observed in 3 (12.0%) and 2 (14.3%) patients in the tacrolimus group and the conventional therapy group, respectively. One cytomegalovirus infection and two herpes zoster infections were noted in the tacrolimus group. All these cases resolved with antiviral treatments. Two cases of renal dysfunction were noted in the conventional therapy group.
IPTW analysis
The survival curves of both groups were adjusted by using IPTW methods. After adjustment, the tacrolimus group had significantly longer event-free survival compared with the conventional therapy group (Fig. 1A) . The weighted HR was 0.32 (95% CI 0.14, 0.75, P = 0.008). In addition, the tacrolimus group had significantly longer disease-free survival compared with the conventional therapy group (Fig. 1B) . The weighted HR was 0.25 (95% CI 0.10, 0.66, P = 0.005).
Discussion
To the best of our knowledge, this retrospective study is the first report statistically demonstrating that the addition of tacrolimus significantly improves the event-free and disease-free survival of patients with PM-/DM-related ILD compared with conventional therapy. Because PM-/DM-related ILD is a life-threatening condition, it is difficult to conduct randomized clinical trials. Therefore it is meaningful that we have shown the efficacy of tacrolimus as an additional treatment of PM-/DM-related ILD using systematic statistical methods.
Corticosteroids are empirically used as first-line therapy for PM-/DM-related ILD. However, >50% of patients were resistant to corticosteroid monotherapy, 20% of patients experienced ILD deterioration and the mortality rate of these refractory patients was 50% [2] . Additional immunosuppressive agents are often necessary in these unfavourable cases. Although various combination therapies have been attempted recently, no consensus treatment has yet been established. Effective treatment protocols are awaited in the near future for severe/ refractory ILD.
T cells are an essential treatment target for PM-/DMrelated ILD. Increased lymphocytes in bronchoalveolar lavage fluid (BALF) have been observed in cases of PM-/DM-related ILD, with a low ratio of CD4 + /CD8 + lymphocytes [18] . Moreover, CD25 + /CD8 + T cells in BALF are significantly increased in corticosteroidresistant PM-/DM-related ILD patients as compared with corticosteroid-sensitive patients [19] . These facts indicate that activated pulmonary T cells play an important role in the development of corticosteroid-resistant PM-/DMrelated ILD. Thus these activated pulmonary T cells in www.rheumatology.oxfordjournals.org patients with PM-/DM-related ILD would be ideal treatment targets. Although CYC is the treatment of choice for PM-/DMrelated ILD, severe patients are often resistant to a single immunosuppressive agent, including CYC [20] . In this study, concomitant use of CYC was more frequent in the tacrolimus group. The better prognosis of the tacrolimus group might be due in part to the effect of concomitant use of CYC.
Our results must be interpreted with caution because of the following limitations. First, this is a retrospective study from a single institution with a relatively small sample size. Second, treatments except tacrolimus were not homogeneous, i.e. initial corticosteroid doses or tapering protocols were determined and practised by the treating physician, and combinations of other immunosuppressive agents such as CYC varied. Therefore, the efficacy of tacrolimus should be confirmed by larger scale, prospective and, if possible, randomized controlled studies. We enrolled consecutive populations who received treatments as initial induction therapy targeting PM-/DMrelated ILD and accounted for variations in patients by performing propensity analysis using the IPTW method. We believe this study is convincing in that tacrolimus improved the prognosis of these patients and has an acceptable safety profile, and we encourage physicians to choose tacrolimus as an additional treatment for patients with severe and difficult conditions.
Rheumatology key messages
. Addition of tacrolimus improved the event-free and disease-free survival of patients with PM-/DMrelated interstitial lung disease. . Tacrolimus is one of the important treatment options for PM-/DM-related interstitial lung disease.
